MetaSight Diagnostics, a health technology company, is on a mission to create affordable and precise liquid biopsy diagnostics for early detection of a variety of chronic and acute diseases, utilizing proprietary, cost-effective mass spectrometry technologies (metabolomics, lipidomics and proteomics). The company has created the world’s largest and most comprehensive serum metabolomics dataset linked with Electronic Health Records and is pursuing additional omics. This unprecedented platform is used by MetaSight’s team of experts in analytical chemistry, AI, and medicine to develop and commercialize diagnostic products to improve human health.
Location: Israel
Employees: 11-50
Total raised: $8M
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.11.2024 | Series A | $8M | - |
Mentions in press and media 2
| Date | Title | Description |
| 13.11.2024 | MetaSight Diagnostics Raises $8M in Over-Subscribed Series A Funding Round | TEL AVIV, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- MetaSight Diagnostics, a health technology company developing multi-omics screening and diagnostic products for several chronic and acute diseases, today announced the closing of an $8 mil... |
| 12.07.2023 | Apparently Getting Smarter Makes Us Healthier: AI And Data Analysis Revolutionize Healthcare | In this age of AI, various fundamental areas of our lives are being transformed. Sometimes this transformation sparks concern, and sometimes, especially when it comes to our health and wellbeing, it ignites tremendous hope. |